Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.
Burger PM, Dorresteijn JAN, Fiolet ATL, Koudstaal S, Eikelboom JW, Nidorf SM, Thompson PL, Cornel JH, Budgeon CA, Westendorp ICD, Beelen DPW, Martens FMAC, Steg PG, Asselbergs FW, Cramer MJ, Teraa M, Bhatt DL, Visseren FLJ, Mosterd A; LoDoCo2 Trial Investigators; UCC-SMART Study Group; REACH Registry Investigators. Burger PM, et al. Among authors: dorresteijn jan. Eur J Prev Cardiol. 2023 Dec 21;30(18):1950-1962. doi: 10.1093/eurjpc/zwad221. Eur J Prev Cardiol. 2023. PMID: 37409348
Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score.
de Winter MA, Dorresteijn JAN, Ageno W, Ay C, Beyer-Westendorf J, Coppens M, Klok FA, Moustafa F, Riva N, Ruiz Artacho PC, Vanassche T, Nijkeuter M. de Winter MA, et al. Among authors: dorresteijn jan. Thromb Haemost. 2022 May;122(5):818-829. doi: 10.1055/s-0041-1735251. Epub 2021 Sep 20. Thromb Haemost. 2022. PMID: 34544170 Clinical Trial.
[Obesity-related hypertension].
Dorresteijn JA, Visseren FL, van den Meiracker AH, Spiering W. Dorresteijn JA, et al. Ned Tijdschr Geneeskd. 2011;154:A1945. Ned Tijdschr Geneeskd. 2011. PMID: 21418695 Review. Dutch.
Decline in risk of recurrent cardiovascular events in the period 1996 to 2014 partly explained by better treatment of risk factors and less subclinical atherosclerosis.
Berkelmans GFN, van der Graaf Y, Dorresteijn JAN, de Borst GJ, Cramer MJ, Kappelle LJ, Westerink J, Visseren FLJ; SMART study group. Berkelmans GFN, et al. Among authors: dorresteijn jan. Int J Cardiol. 2018 Jan 15;251:96-102. doi: 10.1016/j.ijcard.2017.07.026. Epub 2017 Jul 14. Int J Cardiol. 2018. PMID: 28728850 Free article.
SPRINT trial: It's not just the blood pressure!
Berkelmans GF, Visseren FL, Jaspers NE, Spiering W, van der Graaf Y, Dorresteijn JA. Berkelmans GF, et al. Eur J Prev Cardiol. 2017 Sep;24(14):1482-1484. doi: 10.1177/2047487317723213. Epub 2017 Jul 27. Eur J Prev Cardiol. 2017. PMID: 28749177 Clinical Trial.
Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives.
Jaspers NEM, Visseren FLJ, Numans ME, Smulders YM, van Loenen Martinet FA, van der Graaf Y, Dorresteijn JAN. Jaspers NEM, et al. Among authors: dorresteijn jan. BMJ Open. 2018 May 26;8(5):e021309. doi: 10.1136/bmjopen-2017-021309. BMJ Open. 2018. PMID: 29804065 Free PMC article.
94 results